- Home
- SLNO
as 05-12-2025 4:00pm EST
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 3.2B | IPO Year: | 2014 |
| Target Price: | $103.33 | AVG Volume (30 days): | 951.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.93 - $80.91 | Next Earning Date: | 05-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Soleno Therapeutics Inc. (SLNO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hirano Patricia C | SLNO | SEE REMARKS | Apr 1 '25 | Sell | $70.11 | 3,782 | $265,156.02 | 27,036 | |
| Pauls Matthew | SLNO | Director | Mar 28 '25 | Sell | $71.55 | 5,937 | $424,797.10 | 6,500 | |
| Mackaness James H | SLNO | CHIEF FINANCIAL OFFICER | Mar 27 '25 | Sell | $69.46 | 90,622 | $6,293,177.03 | 113,220 | |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Mar 27 '25 | Sell | $68.58 | 699,095 | $47,271,960.10 | 715,084 | |
| Yen Kristen | SLNO | SEE REMARKS | Mar 27 '25 | Sell | $68.72 | 95,500 | $6,376,788.66 | 61,227 | |
| Hirano Patricia C | SLNO | SEE REMARKS | Mar 27 '25 | Sell | $69.39 | 156,315 | $10,709,353.03 | 27,036 | |
| Manning Meredith | SLNO | Chief Commercial Officer | Mar 27 '25 | Sell | $69.03 | 45,249 | $3,044,342.88 | 52,932 | |
| Huang Michael F. | SLNO | Sr. VP of Clinical Development | Mar 27 '25 | Sell | $69.36 | 14,583 | $1,013,627.05 | 39,327 | |
| Vivo Opportunity, LLC | SLNO | 10% Owner | Mar 26 '25 | Sell | $68.07 | 1,833,557 | $124,449,124.20 | 4,791,851 |
Latest Soleno Therapeutics Inc. News
SLNO Breaking Stock News: Dive into SLNO Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now?
GlobeNewswire
4 days ago
Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025
GuruFocus.com
5 days ago
Soleno Therapeutics Inc (SLNO) Q1 2025 Earnings Call Highlights: Navigating Early Success and ...
GlobeNewswire
5 days ago
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
Zacks
7 days ago
Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable
Simply Wall St.
7 days ago
Exploring High Growth Tech Stocks In The US Market
GlobeNewswire
20 days ago
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET
GlobeNewswire
a month ago
Soleno Therapeutics Announces VYKAT(TM) XR Launch
Compare SLNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLNO Soleno Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.